Drugs / Donor-derived CD123-CD16 bispecific antibody-modified NK cells
Donor-derived CD123-CD16 bispecific antibody-modified NK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06835140 | Feb → Dec 2025 overdue | acute myeloid leukemia, lymphoid neoplasm | Chunji Gao | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived CD123-CD16 bispecific antibody-modified NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06835140 ↗ |
| Modality | Cell therapy | “CD123-CD16 bispecific antibody-modified NK cells” NCT06835140 ↗ |
| Route | Intravenous | “intravenously infused with NK cells” NCT06835140 ↗ |